CG Oncology, Inc., a late-stage biopharmaceutical company based in Irvine, United States, operates within the health care sector, focusing on the development and commercialization of a potential bladder-sparing therapeutic for patients affected by bladder cancer. The company’s primary exchange is Nasdaq, where its stock is traded in USD. As of January 9, 2026, CG Oncology’s market capitalization stands at approximately $3.38 billion USD.
In recent developments, CG Oncology reported no new announcements as of early 2026. The most recent public disclosure, issued by Globenewswire on January 6, 2026, highlighted the company’s participation in the 44th Annual J.P. Morgan Healthcare Conference. This event is a significant platform for CG Oncology to present its advancements and strategic directions to investors and industry stakeholders.
Market data from January 7, 2026, indicates that CG Oncology’s stock closed at $41.93. Over the past 52 weeks, the share price has experienced notable volatility, ranging from a low of $14.80 on April 8, 2025, to a high of $46.01 on December 4, 2025. The current price is positioned approximately 63% above the recent low and about 9% below the recent high, suggesting a moderate trading range within the year’s observed extremes.
CG Oncology’s strategic focus remains on advancing its bladder-sparing therapeutic, which holds promise for improving treatment outcomes for bladder cancer patients. The company’s efforts in this area are part of its broader mission to innovate within the medical sector and provide impactful solutions to critical health challenges.
For further information, stakeholders and interested parties can access CG Oncology’s website at www.cgoncology.com , where updates and detailed insights into the company’s operations and developments are regularly posted.
